Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Center for Complementary and Alternative Medicine Special Emphasis Panel, Clinical Trials of Silymarin for Liver Diseases.
Date: December 1, 2005.
Time: 8 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: Double Tree Rockville, 1750 Rockville Pike, Rockville, MD 20852.Start Printed Page 67181
Contact Person: Martina Schmidt, PhD, Scientific Review Administrator, Office of Scientific Review, Nat'l Center for Complementary and Alt Medicine, 6707 Democracy Blvd., Suite 401, Bethesda, MD 20892. 301-594-3456. email@example.com.Start Signature
Dated: October 28, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-21989 Filed 11-3-05; 8:45am]
BILLING CODE 4140-01-M